Seenel Imaging

Seenel Imaging occupies a specialized position at the intersection of research tools, wearable medical devices, and functional neuroimaging. Its core differentiation is the combination of EEG, which captures electrical brain activity, with high-density fNIRS, which measures hemodynamic responses. The MedelOpt platform is extended through wireless mobility, VR compatibility, synchronized dual-headset recordings for hyperscanning, short-channel configurations, and a real-time data API. That breadth makes the company more application-oriented than a single-purpose EEG hardware provider and gives researchers options for laboratory, movement, social-interaction, and immersive-environment studies. The company’s INSERM research origins and stated clinical-neuroscience expertise support credibility in academic and translational settings, while the Biopac Systems Inc. relationship may broaden distribution and integration reach. Its categories place it closer to specialist neurotechnology and research-instrument companies than to mass-market wearables or hospital imaging manufacturers. The three granted patents and newer intrapartum patent activity suggest an effort to extend the platform into clinical monitoring applications, but commercial adoption and clinical validation remain insufficiently documented.

Seenel Imaging’s trajectory appears research-led and product-expansion oriented rather than venture-financing driven. The company was founded in 2004, while Thomas Fontaine became CEO and founder in December 2018, indicating a long operating history followed by a later formalized leadership record. Product development has broadened from the core MedelOpt EEG/fNIRS platform into MedelOpt Mobility for wireless recordings, MedelOpt VR for immersive studies, MedelOpt Tandem for hyperscanning, MeMoSoft for sensor-layout configuration, and the MedelOpt API for application integration. Patent activity provides the strongest measurable inflection point: two intrapartum-related filings were recorded on Jul 21, 2023, followed by an intra-uterine probe record on Sep 10, 2024. These developments suggest movement toward obstetric and clinical monitoring use cases alongside neuroscience research. The company remains small, with an employee range of one to ten and one recorded current position, so growth in headcount cannot be confirmed. Future scale will depend on converting its multimodal platform and patent portfolio into repeatable research, clinical, or distribution revenue.